{Reference Type}: Journal Article
{Title}: Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas.
{Author}: Zhang Y;Wong CH;Hui CWC;Tse T;Yeung V;Cheung K;Tao Q;Loong HH;
{Journal}: Biomed Pharmacother
{Volume}: 176
{Issue}: 0
{Year}: 2024 Jul 13
{Factor}: 7.419
{DOI}: 10.1016/j.biopha.2024.116895
{Abstract}: <B>BACKGROUND: </B>Soft tissue sarcomas (STS) are rare diseases typically arising from connective tissues in children and adults. However, chemotherapies involved in the treatment of STS may cause toxic side effects and multi-drug chemoresistance, making the treatment even more challenging. Histone deacetylase inhibitors (HDACi) are epigenetic agents which have shown anti-tumor effects as single agent as well as combination use with other drugs. Our project intends to prove the same effects in STS.<BR><B>METHODS: </B>Panobinostat (LBH589) plus doxorubicin was selected for investigations based on our previous research. Tumor xenografts were tried in an epithelioid sarcoma model to validate good synergy effects in vivo and a leiomyosarcoma model was used as a negative comparison group. Gene profile changes were studied afterwards. The possible pathway changes caused by HDACi were explored and validated by several assays.<BR><B>RESULTS: </B>Synergy effect of LBH589 plus doxorubicin was successfully validated in STS cell lines and an epithelioid sarcoma mice model. We tried to reduce the dose of doxorubicin to a lower level and found the drug combination can still inhibit tumor size in mice. Furthermore, gene profile changes caused by LBH589 was studied by RNA-Sequencing analysis. Results showed LBH589 can exert effects on a group of target genes which can regulate potential biological functions especially in the cell cycle pathway.